Glofitamab is a CD20xCD3 bispecific antibody developed by F. Hoffmann-La Roche for the treatment of Non-Hodgkin Lymphoma. The FDA is likely to approve glofitamab for the treatment of Non-Hodgkin Lymphoma.

Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Smarter leaders trust GlobalData The gold standard of business intelligence. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Glofitamab overview Glofitamab (Columvi) is a bispecific monoclonal antibody, antineoplastic agent. It is formulated as solution concentrate for the intravenous route of administration. Columvi is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy. Glofitamab is under development for the treatment of B-Cell non-Hodgkin lymphoma, high-grade B-cell lymphoma (HGBCL), marginal zone B-cell lymphoma, mantle cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, follicular lymphoma as a second line therapy and diffuse large B-cell lymphoma as a first line therapy(DLBCL). It is also under development for Burkitt lymphoma. The drug candidate is a T cell-dependent bi-specific antibody (CD20-CD3). It is administered through intravenous route. F. Hoffmann-La Roche overview F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland. For a complete picture of Glofitamab’s drug-specific PTSR and LoA scores, This content was updated on 11 March 2023 Give your business an edge with our leading industry insights. From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s . Smarter leaders trust GlobalData The gold standard of business intelligence.

Link to the original story: https://www.pharmaceutical-technology.com/uncategorized/glofitamab-f-hoffmann-la-roche-non-hodgkin-lymphoma-likelihood-of-approval/